Summary of Treace Medical Concepts (TMCI) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $45.4 million, a decrease of 4% year-over-year.

Gross Margin: 78.5%, down from 79.7% in Q2 2025.

Operating Expenses: Decreased by 8% to $50.6 million.

Net Loss: $15.9 million ($0.24 per share), improved from a net loss of $17.4 million ($0.28 per share) in Q2 2025.

Adjusted EBITDA: Loss of $3.5 million, slightly better than a loss of $3.6 million in the prior year.

Cash Position: Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026. Year-to-date cash usage reduced by 57% compared to the same period in 2025.

2Strategic Updates and Business Highlights

Case Volume Growth: Accelerated to high single digits, driven by increased adoption of new bunion systems and the limited market release of the SuperBite screw system.

Product Portfolio Expansion: Focus on three key initiatives: 1. Drive adoption of three new bunion systems launched in 2025. 2. Advance the Lapiplasty franchise with new technologies. 3. Broaden the product portfolio to include new technologies for adjacent procedures.

Surgeon Adoption: 40% of the Lapiplasty surgeon user base has utilized at least one of the new bunion systems since launch.

New Products: Positive feedback on SuperBite compression screw system and plans for further product launches, including the Lapiplasty Lightning platform and the HyperPlate XM implant.

3Forward Guidance and Outlook

Revenue Guidance: Raised for full year 2026 to a range of $204 million to $212 million, reflecting a decline of 4% to 0% compared to 2025.

Adjusted EBITDA Guidance: Updated to a loss of $3 million to $5 million for the full year, an improvement from previous guidance.

Cash Usage: Expected reduction of approximately 50% for full year 2026 compared to 2025.

Seasonal Strength: Anticipated revenue growth in the fourth quarter, typically the strongest period for the company.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Continued decrease in revenue driven by lower procedure kit sales and a shift towards lower-priced products.

Competitive Pressures: Concerns about how quickly competitors might replicate innovations and the overall competitive landscape in the bunion market.

Market Dynamics: Potential headwinds from the expiration of ACA subsidies and general concerns about elective procedure slowdowns, though no immediate impact has been reported.

5Notable Q&A Insights

Volume and Pricing Dynamics: Surgeons are increasingly adopting new products, contributing to improved case volumes. However, the ASP mix shift due to new product launches continues to impact revenue.

Market Environment: No significant changes in the elective procedure market have been observed, and the company remains optimistic about the upcoming bunion season.

Future Growth Trajectory: Management expressed confidence in sustaining a high single-digit growth trajectory into 2027, supported by a strong fourth quarter and ongoing product innovations. Overall, TMCI's Q2 2026 results reflect a mix of challenges and opportunities, with strategic initiatives aimed at driving growth and improving profitability in the coming quarters.